AXDX - Accelerate Diagnostics Inc. Broker Consensus Forecast

Accelerate Diagnostics (AXDX) possesses limited pricing power due to long-term contracts, utilizing equipment leasing to drive expansion. This price chart illustrates the asset's dynamics, with a valuation of 0.00. The business relies on its status as a global expert in rapid pathogen detection trusted by intensive care unit physicians. Hospital diagnostic systems generate revenue, creating clinic dependency on consumables.

AXDX (Accelerate Diagnostics Inc.) Consensus Target history from 07/04/2022 to 05/24/2025

Analytical breakdowns for Accelerate Diagnostics, Inc (AXDX)

- stock value and consensus price forecast:

Stock Price acceleratediagnostics.com|AXDX - Consensus Target

- market capitalization statistics:

Market Capitalization Accelerate Diagnostics, Inc|AXDX - Enterprise Value

- business book valuation details:

Equity per Share Accelerate Diagnostics|AXDX - Company Net Assets|Capitalization to Book Value Ratio acceleratediagnostics.com|AXDX - Aggregate Company Assets

- debt obligations and liquidity statistics:

Total Debt to Equity Ratio Accelerate Diagnostics|AXDX - Long-Term Debt to Capital|Current Liabilities to Capital Accelerate Diagnostics Inc|AXDX - Company Aggregate Debts|Debt to Book Value Ratio Accelerate Diagnostics, Inc|AXDX - Company Long-Term Debts|Company Short-Term Debts Accelerate Diagnostics|Immediate Liquidity Ratio acceleratediagnostics.com

- net income and valuation multiples indicators:

AXDX - Net Profit|Projected Future Earnings Accelerate Diagnostics|AXDX - Price to Earnings Ratio|Future Price to Earnings Accelerate Diagnostics Inc.|AXDX - Price/Earnings to Growth Multiple|Company Value to EBITDA Accelerate Diagnostics, Inc|AXDX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Accelerate Diagnostics|AXDX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months acceleratediagnostics.com|AXDX - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Accelerate Diagnostics

General company analysis:acceleratediagnostics.com (AXDX)

Original product of Accelerate Diagnostics, Inc.

For Accelerate Diagnostics (AXDX), which is implementing rapid sepsis diagnostics, the shift in the consensus valuation of the stock reflects market confidence in the commercialization of this life-saving technology. This indicator synthesizes the average price targets of independent experts, allowing investors to filter out temporary volatility and timely identify a fundamental trend reversal to avoid locking up capital in a depreciating asset should business metrics deteriorate.

Competing companies